Health Economics›Breast cancer›Metastatic disease all lines of therapy

Metastatic disease all lines of therapy

Breast cancer · 27 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Chlorambucil and Prednisolone Variant #01	—	R 6 768	21d	—	—	—	—	—
Mitoxantrone monotherapy Variant #01	—	R 4 881	21d	—	—	—	—	—
CAF and MPA Variant #01	ER	R 3 735	28d	—	—	—	—	—
CAFVP Variant #01	—	R 2 319	28d	—	—	—	—	—
CEFT Variant #01	—	R 1 685	21d	—	—	—	—	—
Medroxyprogesterone acetate monotherapy Variant #01	ER	R 1 178	28d	—	~6.0 mo	—	—	1
Doxorubicin and Etoposide Variant #01	—	R 1 159	21d	—	—	—	—	—
Fluorouracil monotherapy Variant #16	—	R 858	42d	—	~10.0 mo	—	—	3
Fluorouracil and Methotrexate (MF) Variant #03	—	R 682	14d	—	—	—	—	—
CAMF Variant #01	—	R 528	28d	—	—	—	—	—
CMFP Variant #01	—	R 509	28d	—	—	—	—	—
Estradiol monotherapy Variant #01	ER	R 469	28d	—	—	—	—	—
CMFV Variant #01	—	R 439	28d	—	—	—	—	—
CFP Variant #01	—	R 431	42d	—	—	—	—	—
CMFVP Variant #01	—	R 256	7d	—	—	—	—	—
TAD (Tamoxifen) N/A - secondary systemic drug	ER	R 254	28d	—	—	—	—	—
Aminoglutethimide monotherapy N/A - secondary systemic drug	ER	R 238	28d	—	—	—	—	—
Fluoxymesterone and Tamoxifen Variant #01 Partial	ER	R 137	28d	—	—	—	—	—
Melphalan monotherapy Variant #01	—	R 71	42d	~50.0 mo	~22.2 mo	~37	~R 2 636 PFS proxy · indirect	7
Cyclophosphamide monotherapy N/A - secondary systemic drug	—	R 60	28d	—	22.3 mo	—	—	—
Megestrol monotherapy Variant #01 Partial	ER	—	28d	—	—	—	—	—
Thiotepa monotherapy Variant #01 Partial	—	—	3d	—	—	—	—	—
DES monotherapy Variant #01 Partial	ER	—	28d	—	—	—	—	—
Fluoxymesterone monotherapy Variant #01 Partial	ER	—	28d	—	—	—	—	—
Bilateral oophorectomy Partial	ER	—	—	—	—	—	—	—
Formestane monotherapy Variant #01 Partial	ER	—	14d	—	—	—	—	—
Methotrexate and Thiotepa Variant #01 Partial	—	—	—	—	—	—	—	—

27 of 27 regimens shown